Drugs / NKM
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00846157 Comparator | Sep 2007 → Sep 2011 | diffuse large B-cell lymphoma | NKBio Co.Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00846157 ↗ |
| Modality | Cell therapy | “Natural Killer Cell therapy” NCT00846157 ↗ |
| Route | Intravenous | “100mg IV for 6times” NCT00846157 ↗ |